Boothbay Fund Management’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
SL
Boothbay Fund Management's CGEM Position: Q3 2026 in Review
Boothbay Fund Management reduced its Cullinan Therapeutics (CGEM) stake by 12% in Q3 2026, selling an estimated $2.48M and leaving 953,126 shares worth $14.6M. The position accounts for 0.23% of the portfolio, ranked #82.
Boothbay Fund Management first reported a position in CGEM in Q2 2021 and has held it in 5 quarters since. The position peaked at $19.7M in Q2 2026. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.
- Boothbay Fund Management held 953,126 shares of Cullinan Therapeutics worth $14.6M as of Q3 2026.
- Boothbay Fund Management sold 129,485 Cullinan Therapeutics shares in Q3 2026, an estimated $2.48M.
- Cullinan Therapeutics made up 0.23% of Boothbay Fund Management's portfolio in Q3 2026, its #82 holding.
- Boothbay Fund Management first reported a position in Cullinan Therapeutics in Q2 2021 and has held it in 5 quarters since.
- Boothbay Fund Management's Cullinan Therapeutics position peaked at $19.7M in Q2 2026.
- 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.
Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.